These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9572411)

  • 21. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?
    Orvieto R; Nahum R; Rabinson J; Ashkenazi J; Anteby EY; Meltcer S
    Fertil Steril; 2009 Apr; 91(4 Suppl):1522-5. PubMed ID: 18851846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462).
    Itskovitz-Eldor J; Kol S; Mannaerts B; Coelingh Bennink H
    Hum Reprod; 1998 Feb; 13(2):294-5. PubMed ID: 9557825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol.
    Salgueiro LL; Rolim JR; Moura BR; Machado SP; Haddad C
    JBRA Assist Reprod; 2016 Aug; 20(3):123-6. PubMed ID: 27584604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.
    Griesinger G; Teal V; McCrary Sisk C; Ruman J
    Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():101-105. PubMed ID: 30529793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial.
    Klinkert ER; Broekmans FJ; Looman CW; Habbema JD; te Velde ER
    Hum Reprod; 2005 Mar; 20(3):611-5. PubMed ID: 15591079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bemfola
    Foxon G; Mitchell P; Turner N; McConnell A; Kendrew H; Jenkins J
    Hum Fertil (Camb); 2018 Dec; 21(4):275-280. PubMed ID: 28549400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FSH treatment in infertile males candidate to assisted reproduction improved sperm DNA fragmentation and pregnancy rate.
    Garolla A; Ghezzi M; Cosci I; Sartini B; Bottacin A; Engl B; Di Nisio A; Foresta C
    Endocrine; 2017 May; 56(2):416-425. PubMed ID: 27465288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful induction ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome.
    Kousta E; White DM; Piazzi A; Loumaye E; Franks S
    Hum Reprod; 1996 Jan; 11(1):70-1. PubMed ID: 8671160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A randomized, single-blind, parallel-controlled and multicentre study: compare the efficacy and safety of domestic and imported human recombinant FSH in WHO group Ⅱ anovulatory infertility].
    Zhou YZ; Shen H; Zuo WL; Xu YH; Deng XH; Chen YL; Gao Y; Wang XX; Xu W; Lai QH; Shi H; Liu W; He Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):258-63. PubMed ID: 27116983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization.
    Van Horne AK; Bates GW; Robinson RD; Arthur NJ; Propst AM
    Fertil Steril; 2007 Oct; 88(4):1010-3. PubMed ID: 17434503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased follicle stimulating hormone in infertile men. Guidelines for diagnosis and therapy.
    Comhaire F
    Hum Reprod; 1995 Aug; 10(8):1949-50. PubMed ID: 8567820
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study.
    Papaleo E; Zaffagnini S; Munaretto M; Vanni VS; Rebonato G; Grisendi V; Di Paola R; La Marca A
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():94-99. PubMed ID: 27835829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First established pregnancy and birth after ovarian stimulation with recombinant human follicle stimulating hormone (Org 32489).
    Devroey P; Mannaerts B; Smitz J; Coelingh Bennink H; Van Steirteghem A
    Hum Reprod; 1993 Jun; 8(6):863-5. PubMed ID: 8345075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program].
    Tsagareishvili GG; Khonelidze NL; Lazarev AP
    Georgian Med News; 2005 Jun; (123):7-12. PubMed ID: 16052045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon(R)) by Pen-injector and syringe.
    Voortman G; van de Post J; Schoemaker RC; van Gerven JM
    Hum Reprod; 1999 Jul; 14(7):1698-702. PubMed ID: 10402370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy.
    Papaleo E; Vanni VS; Viganò P; La Marca A; Pagliardini L; Vitrano R; Zanirato M; Marsiglio E; Privitera L; Candiani M
    Gynecol Endocrinol; 2014 Nov; 30(11):813-6. PubMed ID: 24968088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.